"Designing Growth Strategies is in our DNA"

Transthyretin Amyloidosis Treatment Market Size, Share & Industry Analysis, By Drug (Inostersen, Partisiran, Tafamidis, Others), By Indication (Wild Type ATTR amyloidosis, Hereditary ATTR amyloidosis), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy) and Regional Forecast, 2021-2028

In May 2019, the U.S. FDA approved VYNDAQEL (tafamidis meglumine) for the treatment and management of amyloid transthyretin (ATTR) cardiomyopathy, manufactured by Pfizer.... Read More

Final report will be updated to address the impact of COVID-19 on this particular market

Region : Global | Published Date: Upcoming | Report ID: FBI101886 | Status : Upcoming

 

Request PDF Brochure

Refresh Button
Transthyretin Amyloidosis Treatment Market Size, Share and Global Industry Trend Forecast till 2025
  • PDF
  • 2018
  • 2014-2017
  • Direct Purchase
  • 4850
    6850
    8850

Healthcare Clients

3M
abbvie
Amgen
Ansell
Fresenius
Galemed
Grifols
Ipsos
iqvia
Johnson
Jubilant
Lek
Pfizer
Roche
Siemens Healthineers
Styker
uniliver


We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X